Three Ebola vaccines are currently under development to address the Bundibugyo species amid an outbreak in the Democratic Republic of Congo that has claimed nearly 250 lives, with concerns growing that it could escalate into one of the worst outbreaks in history due to limited healthcare resources in the conflict zone where it was detected. #EbolaVaccine #PublicHealth #OutbreakResponse
Amid rising concerns over a potentially severe Ebola outbreak that has claimed nearly 250 lives and exceeds 1,000 suspected cases, three different vaccines—developed by the International Aids Vaccine Initiative, Moderna, and the University of Oxford—are in the pipeline to combat the Bundibugyo species of the virus, which lacks an approved vaccine. #EbolaVaccine #PublicHealth #EpidemicResponse
Scientists at Oxford University are rapidly developing a new vaccine for the rare Bundibugyo Ebola virus, with the potential for clinical trials to begin in two to three months, amidst an ongoing outbreak in the Democratic Republic of Congo that has resulted in 750 suspected cases and 177 deaths. #EbolaVaccine #PublicHealth #VaccineDevelopment
